ProtoKinetix is a pre-revenue, development-stage biotech company focused on researching a synthetic molecule called AAGP® (Anti-Aging Glycoprotein), which mimics antifreeze glycoproteins found in cold-water fish. The company is investigating AAGP®'s potential to protect biological cells, tissues, and organs from stress — primarily the freezing and thawing process used in cryopreservation. ProtoKinetix claims AAGP® can improve cell recovery from cryopreservation by 30% to 120%, and the company is also exploring its use in Type 1 Diabetes treatment, specifically to preserve islet-like cells derived from patient stem cells for potential transplantation therapy. ProtoKinetix has no products, no customers, and no revenue, and has not initiated any clinical trials. The company conducts research through academic collaborators, including past agreements with the University of Alberta and the University of British Columbia. ProtoKinetix's intended future business model involves licensing or selling AAGP®-based products into cell therapy, organ preservation, or cryopreservation markets, though no commercialization timeline exists. The University of Alberta retains a 5% gross revenue royalty on any product developed from research conducted there. The company funds operations entirely through private placements of common stock, carries an accumulated deficit of $48.2M, and operates under a going concern qualification from its auditors. ProtoKinetix's primary balance sheet asset is a capitalized patent portfolio of $470K, whose commercial value remains unproven.